CEACAM5

Summary

CEACAM5 (CEA cell adhesion molecule 5, HGNC:1817) is a protein-coding gene on chromosome 19q13.2, encoding Cell adhesion molecule CEACAM5 (P06731). Cell surface glycoprotein that plays a role in cell adhesion, intracellular signaling and tumor progression.

This gene encodes a cell surface glycoprotein that represents the founding member of the carcinoembryonic antigen (CEA) family of proteins. The encoded protein is used as a clinical biomarker for gastrointestinal cancers and may promote tumor development through its role as a cell adhesion molecule. Additionally, the encoded protein may regulate differentiation, apoptosis, and cell polarity. This gene is present in a CEA family gene cluster on chromosome 19. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 1048 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 123 total
• Druggable target: yes
• MANE Select transcript: NM_004363

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1817
Approved symbol	CEACAM5
Name	CEA cell adhesion molecule 5
Location	19q13.2
Locus type	gene with protein product
Status	Approved
Aliases	CD66e
Ensembl gene	ENSG00000105388
Ensembl biotype	protein_coding
OMIM	114890
Entrez	1048

Gene structure

Transcript identifiers

Ensembl transcripts: 43 — 41 protein_coding, 2 retained_intron

ENST00000221992, ENST00000398599, ENST00000405816, ENST00000460121, ENST00000595113, ENST00000595403, ENST00000596606, ENST00000615021, ENST00000617332, ENST00000888511, ENST00000888512, ENST00000888513, ENST00000888514, ENST00000888515, ENST00000888516, ENST00000888517, ENST00000888518, ENST00000888519, ENST00000888520, ENST00000888521, ENST00000888522, ENST00000888523, ENST00000888524, ENST00000888525, ENST00000888526, ENST00000888527, ENST00000888528, ENST00000888529, ENST00000888530, ENST00000888531, ENST00000888532, ENST00000888533, ENST00000888534, ENST00000888535, ENST00000948421, ENST00000948422, ENST00000948423, ENST00000948424, ENST00000948425, ENST00000948426, ENST00000948427, ENST00000948428, ENST00000948429

RefSeq mRNA: 3 — MANE Select: NM_004363 NM_001291484, NM_001308398, NM_004363

CCDS: CCDS12584, CCDS77302

Canonical transcript exons

ENST00000221992 — 10 exons

Exon	Start	End
ENSE00000842483	41720922	41721176
ENSE00001053043	41727234	41727352
ENSE00001942723	41729184	41730433
ENSE00002458511	41714971	41715249
ENSE00002474363	41717455	41717733
ENSE00002508093	41715650	41715904
ENSE00002519599	41718128	41718382
ENSE00002523265	41719930	41720208
ENSE00003031258	41708626	41708795
ENSE00003567816	41709680	41710039

Expression profiles

Bgee: expression breadth ubiquitous, 180 present calls, max score 99.92.

FANTOM5 (CAGE): breadth broad, TPM avg 6.5749 / max 1910.3682, expressed in 230 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
176051	6.2128	225
176050	0.2729	53
176052	0.0892	25

Top tissues by expression

278 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
colonic mucosa	UBERON:0000317	99.92	gold quality
ileal mucosa	UBERON:0000331	99.92	gold quality
mucosa of sigmoid colon	UBERON:0004993	99.92	gold quality
nasal cavity epithelium	UBERON:0005384	99.73	gold quality
rectum	UBERON:0001052	99.66	gold quality
mucosa of transverse colon	UBERON:0004991	99.49	gold quality
esophagus squamous epithelium	UBERON:0006920	99.09	gold quality
pharyngeal mucosa	UBERON:0000355	99.07	gold quality
tongue squamous epithelium	UBERON:0006919	98.56	gold quality
vermiform appendix	UBERON:0001154	98.49	gold quality
lower esophagus mucosa	UBERON:0035834	98.40	gold quality
oral cavity	UBERON:0000167	98.39	gold quality
epithelium of esophagus	UBERON:0001976	98.27	gold quality
palpebral conjunctiva	UBERON:0001812	97.87	gold quality
trachea	UBERON:0003126	97.56	gold quality
esophagus mucosa	UBERON:0002469	96.74	gold quality
caecum	UBERON:0001153	95.98	gold quality
squamous epithelium	UBERON:0006914	95.78	gold quality
buccal mucosa cell	CL:0002336	95.74	gold quality
epithelium of nasopharynx	UBERON:0001951	95.62	gold quality
nasopharynx	UBERON:0001728	95.61	gold quality
cervix epithelium	UBERON:0004801	95.50	gold quality
cervix squamous epithelium	UBERON:0006922	93.07	gold quality
transverse colon	UBERON:0001157	92.77	gold quality
body of tongue	UBERON:0011876	92.35	gold quality
pancreatic ductal cell	CL:0002079	92.04	gold quality
nasal cavity mucosa	UBERON:0001826	91.02	gold quality
gingiva	UBERON:0001828	90.49	gold quality
gingival epithelium	UBERON:0001949	88.78	gold quality
jejunal mucosa	UBERON:0000399	88.60	gold quality

Single-cell (SCXA)

Detected in 8 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-MTAB-8410	yes	4593.03
E-GEOD-125970	yes	3798.88
E-CURD-114	yes	1034.74
E-GEOD-75688	yes	626.93
E-GEOD-86618	no	1689.41
E-ENAD-27	no	3.90
E-MTAB-4850	no	1.55
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CTNNB1, HIF1A, MYC, SP1, TBXT, TCF7, USF1, USF2

miRNA regulators (miRDB)

62 targeting CEACAM5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1193	100.00	65.93	529
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-3617-3P	99.98	67.86	918
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-6793-5P	99.97	65.95	758
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-556-3P	99.74	68.75	1203
HSA-MIR-10393-3P	99.72	66.56	961
HSA-MIR-6801-5P	99.72	66.50	981
HSA-MIR-7154-5P	99.69	70.52	1900
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-4743-3P	99.62	68.12	2095
HSA-MIR-105-5P	99.54	69.24	2060
HSA-MIR-7853-5P	99.54	69.30	2055
HSA-MIR-513A-3P	99.39	70.63	3620
HSA-MIR-513C-3P	99.39	70.63	3620
HSA-MIR-6853-3P	99.36	70.79	1558
HSA-MIR-2115-3P	99.31	69.68	2026
HSA-MIR-504-3P	99.30	67.18	1745
HSA-MIR-4477B	99.23	70.49	1733
HSA-MIR-3606-3P	99.11	69.84	3254
HSA-MIR-3152-3P	99.10	66.35	678
HSA-MIR-7702	99.06	65.95	698
HSA-MIR-520G-3P	98.91	67.38	1914
HSA-MIR-520H	98.91	67.38	1914

Literature-anchored findings (GeneRIF, showing 40)

• Inhibition of carcinoembryonic antigen increases apoptotic rate of colon cancer cells and inhibits metastatic tumor growth (PMID:11964079)
• Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. (PMID:12237895)
• white blood cells express a splice variant of CEA , which hinders detection of tumor cell cDNA in whole blood samples (PMID:12420218)
• results suggest that CEA and CK 20 mRNA identification by RT-PCR appeared to be reliable and may be useful for early diagnosis in peritoneal dissemination of colon cancer (PMID:12636102)
• value of this tumor marker regarding relapse, metastasis and death in resectable non-small cell lung cancer (PMID:14566828)
• the results show that recognition of CEA and CEACAM6, but not CEACAM1, is accompanied by tight attachment to bacteria of cell surface microvilli-like extensions (PMID:15130118)
• SB1a and CEA in the patches on the cell surface of human colon adenocarcinoma cells could be biologically important ligands for galectin-4 (PMID:15546874)
• Heterophilic interactions of carcinoembryonic antigen and CEACAM1 inhibit killing by natural killer (NK) cells. The N-terminal domain of CEACAM1 is crucial but not sufficient for both CEACAM1-CEACAM1 homophilic and CEACAM1-CEA heterophilic interactions. (PMID:15905509)
• CEA and CK19 expression was higher in lung cancer patients than in patients with benign lung diseases and healthy controls. (PMID:16324274)
• significantly increased in transformed trophoblast of gestational trophoblastic diseases (PMID:16574224)
• Intensive follow-up by serial assay of CEA and cytokeratins allows early detection of colorectal neoplasm recurrence. (PMID:16804977)
• Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8(+) CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells. (PMID:17016692)
• CEACAM6 expression is elevated in many solid tumors and may be a promising target for antibody-based therapy for cancer. (PMID:17201906)
• CEA-mediated signaling involves clustering of CEA and co-clustering and activation of the alpha5beta1 and associated specific signaling elements on the internal surfaces of membrane microdomains (PMID:17286276)
• TNM staging, preoperative CEA and CD44v6 were independent prognostic factors for rectal cancer patients with total mesorectal excision. (PMID:17589956)
• findings suggest that CEA (CEACAM5) and CEACAM6 are major target genes for Smad3-mediated TGF-beta signaling. (PMID:17653079)
• Results show that measurements of AFP, CEA and CA125 are more readily affected by long-term frozen storage compared with frequent freezing-thawing. (PMID:17852813)
• CEA mRNA copy number, not positivity, was significantly associated with postoperative term of recurrent gastric cancer. (PMID:17936797)
• The serum CEA level appears to be closely associated with the presence of EGFR gene mutations in patients with pulmonary adenocarcinomas. (PMID:17941001)
• Cigarette smoking was associated with increased serum carcinoembryonic antigen (CEA) levels in a dose- and duration-dependent manner and association between serum CEA and carotid plaque was significant (PMID:17951321)
• elevated level of CEA has a strong negative prognostic impact on survival in operated early stage of non-small cell lung cancer (PMID:18083270)
• serum MMP-9, SCC-Ag and CEA were not significant for prognosis of esophageal cancer (PMID:18155162)
• possibility of observing many clinical reactions could be shown for CEA652 (9) in cases where positive conversion was observed (PMID:18219853)
• CEA and CD44v cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin at elevated shear stresses. (PMID:18375392)
• The levels of CEA in pleural effusion and serum of patients with lung cancer were much higher than those with benign lung disease. (PMID:18394347)
• Serum samples were investigated for carcinoembryonic antigen (CEA), CA125 and MUC1, alpha-foetoprotein, neuron-specific enolase and CA19.9. (PMID:18609108)
• mRNA expression of LUNX, CK19 and CEA genes in the regional lymph nodes of NSCLC was significantly higher than that in those of benign lung diseases. (PMID:18646695)
• Elevated carcinoembryonic antigen is associated with recurrence after curative resection of colorectal cancer. (PMID:18846401)
• Human eccrine sweat glands express CK7, CK8, CK14, CK18, CK19, CEA, EMA, Ki67, p63, EGF and EGFR. In skin, CEA can be used as a specific immunological marker of sweat glands. (PMID:19032382)
• CK20 and CEA are expressed in non-macroscopically involved lymph nodes of colorectal cancer. (PMID:19074466)
• CEA was a highly significant predictor of response to therapy and survival in both limited disease and extensive disease small cell lung cancer patients. Normal serum CEA level was associated with improved response rate. (PMID:19214813)
• A CEA level </= 2.5 ng/ml might be a predictor not only of tumor response, as has been suggested before, but also of disease-free survival. (PMID:19259690)
• Increased carcinoembryonic antigen level is associated with oral and salivary malignant tumors. (PMID:19322585)
• The utility of the tumour markers carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 19-9, carbohydrate antigen 15-3, alpha-fetoprotein and human chorionic gonadotropin for the diagnosis solitary pulmonary nodules, was investigated. (PMID:19383238)
• High CEA serum level is a risk factor for brain metastasis development and is associated with poor prognosis in patients with advanced NSCLC. (PMID:19386089)
• the percentage of lung carcinoma patients remaining unclassifiable by TTF-1/TP63 was twice that of the five-antibody (TRIM29, CEACAM5, SLC7A5, MUC1, and CK5/6) test (PMID:19430419)
• Ppreoperative CEA level was a very good predictor of the pathological stage in stage I non-small cell lung cancer. (PMID:19457896)
• CEA expression in melanomas, dysplastic nevi \and primary superficial spreading melanoma was significantly increased (PMID:19461083)
• The three markers (ER, Vim and CEA) and their respective panel expressions showed statistically significant (p < 0.05) frequency differences between endocervical adenocarcinomas and endometrial adenocarcinomas tumors. (PMID:19476621)
• Data show that mice express human CEA, present epitopes solely through HLA-A2.1 molecules and constitute a unique in vivo animal model to study HLA-A2.1-restricted immune response of a human CEA-based vaccine. (PMID:19561534)

Cross-species orthologs

0 orthologs

Paralogs (24): CEACAM21 (ENSG00000007129), CEACAM7 (ENSG00000007306), CEACAM1 (ENSG00000079385), CEACAM6 (ENSG00000086548), CEACAM4 (ENSG00000105352), PSG8 (ENSG00000124467), CEACAM8 (ENSG00000124469), HEPACAM (ENSG00000165478), PSG6 (ENSG00000170848), CEACAM3 (ENSG00000170956), PSG9 (ENSG00000183668), CEACAM19 (ENSG00000186567), HEPACAM2 (ENSG00000188175), PSG5 (ENSG00000204941), CEACAM18 (ENSG00000213822), CEACAM16 (ENSG00000213892), VSTM5 (ENSG00000214376), PSG3 (ENSG00000221826), PSG7 (ENSG00000221878), PSG1 (ENSG00000231924), PSG2 (ENSG00000242221), PSG11 (ENSG00000243130), PSG4 (ENSG00000243137), CEACAM20 (ENSG00000273777)

Protein

Protein identifiers

Cell adhesion molecule CEACAM5 — P06731 (reviewed: P06731)

Alternative names: Carcinoembryonic antigen, Carcinoembryonic antigen-related cell adhesion molecule 5, Meconium antigen 100

All UniProt accessions (6): P06731, A0A024R0K5, A0A087WYX0, M0QX98, M0R3J1, T2HUW8

UniProt curated annotations — full annotation on UniProt →

Function. Cell surface glycoprotein that plays a role in cell adhesion, intracellular signaling and tumor progression. Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM6. Plays a role as an oncogene by promoting tumor progression; induces resistance to anoikis of colorectal carcinoma cells. (Microbial infection) Receptor for E.coli Dr adhesins. Binding of E.coli Dr adhesins leads to dissociation of the homodimer.

Subunit / interactions. Homodimer.

Subcellular location. Cell membrane. Apical cell membrane. Cell surface.

Tissue specificity. Expressed in columnar epithelial and goblet cells of the colon (at protein level). Found in adenocarcinomas of endodermally derived digestive system epithelium and fetal colon.

Post-translational modifications. Complex immunoreactive glycoprotein with a MW of 180 kDa comprising 60% carbohydrate.

Similarity. Belongs to the immunoglobulin superfamily. CEA family.

Isoforms (2)

UniProt ID	Names	Canonical?
P06731-1	1	yes
P06731-2	2

RefSeq proteins (3): NP_001278413, NP_001295327, NP_004354* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013106	Ig_V-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR050831	CEA_cell_adhesion	Family

Pfam: PF07686, PF13895, PF13927

UniProt features (98 total): glycosylation site 28, strand 21, mutagenesis site 14, domain 7, sequence variant 7, disulfide bond 6, turn 4, sequence conflict 3, helix 3, signal peptide 1, chain 1, lipid moiety-binding region 1, propeptide 1, splice variant 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
1E07	SOLUTION SCATTERING	0
2QSQ	X-RAY DIFFRACTION	1.95
9U93	ELECTRON MICROSCOPY	2.4
2QST	X-RAY DIFFRACTION	2.9
8BW0	ELECTRON MICROSCOPY	3.11
2VER	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P06731-F1	87.44	0.72

Antibody-complex structures (SAbDab): 1 — 8BW0

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 676

Disulfide bonds (6): 167–215, 259–299, 345–393, 437–477, 523–571, 615–655

Glycosylation sites (28): 104, 115, 152, 182, 197, 204, 208, 246, 256, 274, 288, 292, 309, 330, 351, 360, 375, 432, 466, 480 …

Mutagenesis-validated functional residues (14):

Position	Phenotype
63	no effect on dimerization. reduced affinity for e.coli dr adhesins.
63	abolishes dimerization. reduced affinity for e.coli dr adhesins.
66	abolishes dimerization.
68	abolishes dimerization.
68	no effect on dimerization.
69	abolishes dimerization.
73	abolishes dimerization.
74	no effect on dimerization.
74	abolishes dimerization.
78	abolishes dimerization. reduced affinity for e.coli dr adhesins.
125	abolishes dimerization. reduced affinity for e.coli dr adhesins.
129	no effect on dimerization. reduced affinity for e.coli dr adhesins.
129	abolishes dimerization. reduced affinity for e.coli dr adhesins.
133	abolishes dimerization.

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-163125	Post-translational modification: synthesis of GPI-anchored proteins
R-HSA-202733	Cell surface interactions at the vascular wall
R-HSA-109582	Hemostasis
R-HSA-392499	Metabolism of proteins
R-HSA-597592	Post-translational protein modification

MSigDB gene sets: 115 (showing top): GOBP_HETEROPHILIC_CELL_CELL_ADHESION, GOBP_NEGATIVE_REGULATION_OF_STRIATED_MUSCLE_CELL_DIFFERENTIATION, GOBP_NEGATIVE_REGULATION_OF_MUSCLE_CELL_DIFFERENTIATION, GOZGIT_ESR1_TARGETS_DN, GOBP_STRIATED_MUSCLE_CELL_DIFFERENTIATION, GOCC_CELL_SURFACE, GOBP_REGULATION_OF_STRIATED_MUSCLE_CELL_DIFFERENTIATION, GOBP_NEGATIVE_REGULATION_OF_MYOTUBE_DIFFERENTIATION, USF_C, GOBP_CELL_CELL_ADHESION, GOBP_MUSCLE_STRUCTURE_DEVELOPMENT, SMID_BREAST_CANCER_LUMINAL_B_UP, GOBP_REGULATION_OF_MUSCLE_CELL_DIFFERENTIATION, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5, GOBP_NEGATIVE_REGULATION_OF_ANOIKIS

GO Biological Process (8): apoptotic process (GO:0006915), homophilic cell-cell adhesion (GO:0007156), heterophilic cell-cell adhesion (GO:0007157), negative regulation of myotube differentiation (GO:0010832), homotypic cell-cell adhesion (GO:0034109), negative regulation of apoptotic process (GO:0043066), negative regulation of anoikis (GO:2000811), cell adhesion (GO:0007155)

GO Molecular Function (4): GPI anchor binding (GO:0034235), identical protein binding (GO:0042802), protein homodimerization activity (GO:0042803), protein binding (GO:0005515)

GO Cellular Component (8): extracellular region (GO:0005576), plasma membrane (GO:0005886), cell surface (GO:0009986), membrane (GO:0016020), basolateral plasma membrane (GO:0016323), apical plasma membrane (GO:0016324), extracellular exosome (GO:0070062), side of membrane (GO:0098552)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Post-translational protein modification	1
Hemostasis	1
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
cell-cell adhesion	3
membrane	2
plasma membrane region	2
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
regulation of myotube differentiation	1
myotube differentiation	1
negative regulation of striated muscle cell differentiation	1
apoptotic process	1
regulation of apoptotic process	1
negative regulation of programmed cell death	1
negative regulation of apoptotic process	1
anoikis	1
regulation of anoikis	1
cellular process	1
phospholipid binding	1
glycolipid binding	1
protein binding	1
identical protein binding	1
protein dimerization activity	1
binding	1
cell periphery	1
basal plasma membrane	1
apical part of cell	1
extracellular vesicle	1
leaflet of membrane bilayer	1

Protein interactions and networks

STRING

2316 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CEACAM5	AFP	P02771	941
CEACAM5	MUC1	P13931	922
CEACAM5	ENO2	P09104	919
CEACAM5	CD209	Q9NNX6	887
CEACAM5	KRT7	P08729	883
CEACAM5	CEACAM1	P13688	880
CEACAM5	KRT19	P08727	871
CEACAM5	KRT20	P35900	847
CEACAM5	KLK3	P07288	821
CEACAM5	LIAT1	Q6ZQX7	788
CEACAM5	CRP	P02741	769
CEACAM5	ERBB2	P04626	764
CEACAM5	KRT5	P13647	753
CEACAM5	EPCAM	P16422	746
CEACAM5	ALB	P02768	728
CEACAM5	GPT	P24298	728

IntAct

29 interactions, top by confidence:

A	B	Type	Score
CEACAM5	CEACAM5	psi-mi:“MI:0407”(direct interaction)	0.760
CEACAM5	CEACAM1	psi-mi:“MI:0915”(physical association)	0.610
CEACAM1	CEACAM5	psi-mi:“MI:0407”(direct interaction)	0.610
S	CEACAM5	psi-mi:“MI:0915”(physical association)	0.520
CEACAM5	S	psi-mi:“MI:0915”(physical association)	0.520
CEACAM5	CD8A	psi-mi:“MI:0407”(direct interaction)	0.440
CD1D	CEACAM5	psi-mi:“MI:0407”(direct interaction)	0.440
draE	CEACAM5	psi-mi:“MI:0407”(direct interaction)	0.440
CEACAM5		psi-mi:“MI:0407”(direct interaction)	0.440
	CEACAM5	psi-mi:“MI:0407”(direct interaction)	0.440
SELE	CEACAM5	psi-mi:“MI:0915”(physical association)	0.400
CEACAM6	CEACAM5	psi-mi:“MI:0915”(physical association)	0.400
CEACAM5	afaE3	psi-mi:“MI:0915”(physical association)	0.400
UQCC2	CEACAM5	psi-mi:“MI:0915”(physical association)	0.370
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350
FNDC5	A2ML1	psi-mi:“MI:0914”(association)	0.350

BioGRID (20): EWSR1 (Two-hybrid), CEACAM5 (Affinity Capture-MS), CEACAM5 (Reconstituted Complex), CEACAM5 (Affinity Capture-Western), S (Affinity Capture-Western), Hnrnpm (Two-hybrid), CEACAM5 (Affinity Capture-Western), CEACAM5 (Proximity Label-MS), CEACAM5 (Affinity Capture-MS), CEACAM5 (Affinity Capture-MS), CEACAM5 (Affinity Capture-Western), CEACAM5 (Affinity Capture-MS), CEACAM5 (Negative Genetic), CEACAM5 (Affinity Capture-MS), CEACAM5 (Co-fractionation)

ESM2 similar proteins: A0A0B4J2E0, D3ZQE1, E9QA28, O00478, O00481, O75019, O75871, P01733, P06731, P0C191, P11464, P11465, P13688, P16573, P31809, P31997, P40198, P40199, P59901, Q00887, Q00888, Q00889, Q13046, Q13410, Q14002, Q15238, Q16557, Q28110, Q2WEN9, Q3KPI0, Q3UKK2, Q61400, Q63111, Q6PI73, Q810J1, Q863H2, Q8C567, Q8MJZ2, Q8N149, Q8N6C8

Diamond homologs: A0A0B4J1L0, D3ZQE1, E9QA28, O75871, P06731, P11464, P11465, P13688, P16573, P31809, P31997, P40198, P40199, Q00887, Q00888, Q00889, Q13046, Q14002, Q15238, Q16557, Q2WEN9, Q3KPI0, Q3UKK2, Q61400, Q63111, Q810J1, Q925P2, Q9D2Z1, Q9UQ72, Q9UQ74, A0A8M2B818, B0JYH6, B4KPU0, P15151, P20273, P32506, P32507, Q15223, Q5FWR8, Q92692

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

123 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	90
Likely benign	7
Benign	16

Top pathogenic / likely-pathogenic (0)

SpliceAI

1645 predictions. Top by Δscore:

Variant	Effect	Δscore
19:41710040:G:GG	donor_gain	1.0000
19:41719926:ACAGC:A	acceptor_gain	1.0000
19:41719929:GC:G	acceptor_gain	1.0000
19:41719929:GCGGA:G	acceptor_gain	1.0000
19:41727218:ATGAC:A	acceptor_gain	1.0000
19:41727219:T:G	acceptor_gain	1.0000
19:41708734:G:GT	donor_gain	0.9900
19:41708802:G:GT	donor_gain	0.9900
19:41708803:G:T	donor_gain	0.9900
19:41709678:A:AC	acceptor_loss	0.9900
19:41709678:A:AG	acceptor_gain	0.9900
19:41709679:G:GA	acceptor_gain	0.9900
19:41709679:G:GC	acceptor_loss	0.9900
19:41709679:G:GG	acceptor_gain	0.9900
19:41709679:G:T	acceptor_loss	0.9900
19:41709679:GCCT:G	acceptor_gain	0.9900
19:41709679:GCCTC:G	acceptor_gain	0.9900
19:41710037:ACCGT:A	donor_loss	0.9900
19:41710038:CCGT:C	donor_loss	0.9900
19:41710039:CG:C	donor_loss	0.9900
19:41710039:CGT:C	donor_loss	0.9900
19:41710040:G:GC	donor_loss	0.9900
19:41710041:T:G	donor_loss	0.9900
19:41710042:G:GA	donor_loss	0.9900
19:41710043:A:AA	donor_loss	0.9900
19:41714967:ACAGC:A	acceptor_gain	0.9900
19:41714968:C:G	acceptor_gain	0.9900
19:41714969:A:AG	acceptor_gain	0.9900
19:41714969:AGC:A	acceptor_gain	0.9900
19:41714969:AGCG:A	acceptor_gain	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000204119 (19:41709798 T>A,C), RS1000562935 (19:41722130 G>A), RS1000571883 (19:41716346 T>C), RS1001088272 (19:41710718 C>T), RS1001236321 (19:41725181 A>G), RS1001477196 (19:41713464 T>C), RS1001515290 (19:41721802 G>T), RS1001604103 (19:41730901 A>G), RS1001935848 (19:41729475 C>A,T), RS1002050948 (19:41729873 G>A,C), RS1002312459 (19:41708219 C>T), RS1002787923 (19:41726421 A>G), RS1002972513 (19:41710581 C>A), RS1003270386 (19:41710247 G>T), RS1003319296 (19:41709480 G>T)

Disease associations

OMIM: gene MIM:114890 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST004735_30	Epstein-Barr virus copy number in lymphoblastoid cell lines	2.000000e-06
GCST009650_10	Serum carcinoembryonic antigen levels	7.000000e-09
GCST009650_4	Serum carcinoembryonic antigen levels	5.000000e-201
GCST009650_7	Serum carcinoembryonic antigen levels	4.000000e-20
GCST009650_8	Serum carcinoembryonic antigen levels	2.000000e-18

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0005760	serum carcinoembryonic antigen measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3712881 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — CD molecules

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	decreases expression, affects cotreatment, increases expression	3
sodium arsenite	decreases expression, increases expression	2
Air Pollutants	increases expression, increases abundance	2
Benzo(a)pyrene	affects methylation, affects cotreatment, affects expression	2
Silicon Dioxide	decreases expression	2
Smoke	increases abundance, increases expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
bisphenol A	increases expression	1
beta-lapachone	increases expression	1
tetrathiomolybdate	decreases expression	1
tri-o-cresyl phosphate	increases expression	1
1,2,5,6-dibenzanthracene	increases expression	1
1-methylphenanthrene	affects cotreatment, affects expression	1
dibenzo(a,l)pyrene	affects cotreatment, affects expression	1
NSC 689534	increases expression	1
(+)-JQ1 compound	decreases expression	1
Zoledronic Acid	increases expression	1
Vorinostat	affects cotreatment, increases expression	1
Diazinon	increases methylation	1
Drugs, Chinese Herbal	increases expression	1
Hydrogen Peroxide	affects expression	1
Lead	decreases expression	1
Methotrexate	increases expression	1
Nickel	decreases expression	1
Polycyclic Aromatic Hydrocarbons	affects expression	1
Progesterone	affects cotreatment, decreases expression	1
Quercetin	decreases expression	1
Tetrachlorodibenzodioxin	affects cotreatment, increases expression	1
Tretinoin	increases expression	1
Isotretinoin	affects cotreatment, increases expression	1

Cellosaurus cell lines

12 cell lines: 9 cancer cell line, 2 transformed cell line, 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_5I36	MC-38-CEA-1	Cancer cell line	Female
CVCL_5I37	MC-38-CEA-2	Cancer cell line	Female
CVCL_B8DK	Abcam HCT 116 CEACAM5 KO	Cancer cell line	Male
CVCL_B8U2	Abcam MCF-7 CEACAM5 KO	Cancer cell line	Female
CVCL_B9FT	Abcam A-549 CEACAM5 KO	Cancer cell line	Male
CVCL_C0EJ	HEK293-CEACAM5-Fc	Transformed cell line	Female
CVCL_C9CQ	MIP-CEA clone 17	Cancer cell line	Male
CVCL_C9CR	MIP-CEA clone 6	Cancer cell line	Male
CVCL_C9CS	MIP-CEA clone 8	Cancer cell line	Male
CVCL_E6PW	Genomeditech CHO-K1 H_CEACAM5(CEA)	Spontaneously immortalized cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.